$2.04
Value $445M
CTMX and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$2.04
Value $445M
$700.22
Value $260B
CytomX Therapeutics (CTMX) has a market value of $445M and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, CTMX moved -51.8% and TMO +19.5%. Dividend yield: CTMX none, TMO 0.26%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CTMX$445M
TMO$260B
TMO is 585 times CTMX
Revenue, 12 months
CTMX$14M
TMO$47.4B
TMO is 3,376 times CTMX
Net income, 12 months
CTMX-$85M
TMO$7.1B
Operating margin
CTMX-676.5%
TMO17.9%
694.3 points apart
ROIC
CTMX-33.7%
TMO8.2%
41.9 points apart
P/E
CTMX–
TMO36.8
Dividend yield
CTMX0.0%
TMO0.3%
0.3 points apart
5-year return
CTMX-70.9%
TMO+11.8%
82.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CTMX-70.9%
TMO+11.8%
| Period | CTMXWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -51.8%Price -51.8% | +19.5%Price +19.1% |
| 3 years since November 13, 2023 | +65.9%+18.4% a yearPrice +65.9% | +58.8%+16.7% a yearPrice +57.3% |
| 5 years since November 12, 2021 | -70.9%-21.9% a yearPrice -70.9% | +11.8%+2.3% a yearPrice +10.2% |
| 10 years since November 15, 2016 | -82.2%-15.9% a yearPrice -82.2% | +384.5%+17.1% a yearPrice +371.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CTMXCytomX TherapeuticsTMOThermo Fisher Scientific
| Price | $2.04 | $700.22 |
|---|---|---|
| Market value | $445M | $260B |
| Enterprise value (EV) | $97M | $295B |
| P/E | – | 36.8 |
| P/E, 5-year median | – | 32.7 |
| P/B | 1.6 | 4.8 |
| EV/EBIT | – | 34.9 |
| Free cash flow yield | – | 2.9% |
| Revenue, 12 months | $14M | $47.4B |
|---|---|---|
| Net income, 12 months | -$85M | $7.1B |
| Free cash flow, 12 months | -$51M | $7.6B |
| Earnings per share, 12 months | -$0.50 | $18.96 |
| Revenue growth, year on year | -44.8% | 3.9% |
| Revenue growth a year, past | +2.2%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | – | – |
|---|---|---|
| Operating margin | -676.5% | 17.9% |
| Net margin | -609.0% | 14.9% |
| ROIC | -33.7% | 8.2% |
| ROE | -38.4% | 13.4% |
| Cash | $348M | $6.1B |
|---|---|---|
| Total debt | $4.4M | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | – | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($260B) is about 584.9 times CytomX Therapeutics ($445M), at today's prices.
Since November 15, 2016, CTMX's price moved -82.2% and TMO's +371.0%. With dividends: CTMX -82.2% (-15.9% a year), TMO +384.5% (+17.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for CytomX Therapeutics and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
Over the last twelve months, the net margin was -609.0% for CytomX Therapeutics and 14.9% for Thermo Fisher Scientific, and the operating margin -676.5% and 17.9%. Revenue was $14M and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.